FILTERED RESULTS
FILTERS
Ads Top
DARK MODE
CHART
    Filters
      Symbols
      Sentiment
      Impact
      Search
      FILTERED RESULTS

        

      Upgrade your plan

      Citi Increases Price Target for Gilead Sciences Ahead of Q1 Preview

      Citi analyst Geoff Meacham has raised the price target for Gilead Sciences, Inc. to $165 from a previous target of $156. This adjustment reflects the firm's continued confidence in Gilead's performance and comes alongside a Buy rating on the company's shares.

      Gilead Sciences is recognized as one of the top ten healthcare stocks with the highest dividends, highlighting its strong position in the biopharmaceutical sector. The price target increase is part of Citi's broader preview for the first quarter, indicating positive expectations for the company's upcoming financial results.

      © 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

      Source: KLEA News

      .

      Terra Founder Do Kwon Sentenced to 15 Years in Prison for Fraud